BioHorizons Adds Prolifica Allogeneic Growth Factor to Biomaterials Portfolio - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

BioHorizons Adds Prolifica Allogeneic Growth Factor to Biomaterials Portfolio

New option uses biphasic protein release to support bone healing and tissue regeneration.

  • By

  • News Staff

  • August 26, 2026

Share

Objective:

To introduce Prolifica™, an allogeneic growth factor for bone healing and tissue regeneration.

Approach:
  • Product Description: Prolifica contains a blend of allogeneic growth factors and preserves a biphasic release of proteins.
  • Mechanism: It provides an initial release of proteins to support healing, followed by prolonged release for continued support.
  • Protein Composition: Prolifica retains a minimum of 16 proteins related to cell growth, division, bone healing, and tissue regeneration.
  • Application: It can be used in standalone bone grafting or in combination with autologous or allograft bone.
Key Findings:
  • Prolifica supports complex hard tissue regenerative procedures.
  • The product is designed to maintain a high concentration of growth factors.
Interpretation:

Prolifica is positioned as an advanced solution for surgeons dealing with bone grafting in aging populations.

Conclusion:

Prolifica aims to enhance outcomes in bone healing and tissue regeneration.

Sources:

Original Source(s)

BioHorizons Adds Prolifica Allogeneic Growth Factor to Biomaterials Portfolio

  • by News Staff

  • August 26, 2026

Related Content

Medical Oddities: When a Brush Beats a Scalpel

This research roundup has brain drama, bleeding control, skin science, and tiny brushes.

Beyond the dose-volume histogram: a critical appraisal of normal tissue complication probability modelling for osteoradionecrosis of the jaw and a strategic framework for clinical translation

Francisco Partners to Acquire Weave for Approximately $650 Million

Healthcare technology company would become privately held following completion of the transaction.